rna
interfer
rnai
becom
method
choic
suppress
gene
express
vitro
also
emerg
power
tool
vivo
research
studi
publish
use
synthet
small
interf
rna
mammal
report
demonstr
potenti
use
synthet
small
interf
rna
sirna
therapeut
agent
especi
area
cancer
viral
infect
number
report
use
sirna
function
genom
applic
valid
target
smallmolecul
drug
develop
program
address
question
basic
biolog
rapidli
grow
method
protocol
use
anim
becom
establish
review
first
discuss
aspect
rnai
biochemistri
biolog
impact
vivo
use
especi
relat
experiment
design
provid
overview
publish
work
focu
methodolog
compound
select
alter
express
level
gene
sought
basic
scientist
clinician
mani
year
nucleic
acid
hybrid
specif
theoret
sequenc
desir
gene
could
uniqu
target
oligonucleotid
complementari
sequenc
first
bantisenseq
experi
perform
year
ago
employ
dna
oligonucleotid
block
translat
rou
sarcoma
viru
rna
experi
demonstr
use
antisens
rna
inhibit
gene
express
soon
follow
antisens
method
use
singlestrand
dna
ssdna
singlestrand
rna
ssrna
oligonucleotid
reli
upon
either
rnase
hmediat
degrad
target
mrna
steric
blockad
translat
mechan
action
howev
pathway
exploit
favor
result
exampl
trigger
action
rnase
l
conjug
antisens
oligonucleotid
sequenc
enabl
sequencespecif
target
otherwis
nonspecif
ribonucleas
extens
medicin
chemistri
done
antisens
nucleic
acid
hundr
compound
test
search
modif
improv
nucleas
stabil
increas
bind
affin
melt
temperatur
improv
vivo
pharmacodynam
properti
oligonucleotid
drug
pharmaceut
compani
work
develop
antisens
drug
year
extens
knowledg
pharmacolog
toxicolog
synthet
nucleic
acid
vivo
compil
one
antisens
drug
market
formivirsen
vitraven
product
isi
pharmaceut
novarti
ophthalm
phosphorothio
dna
oligonucleotid
complementari
immedi
earli
region
cytomegaloviru
cmv
compound
shown
effect
treatment
cmv
retin
approv
fda
use
direct
intravitr
inject
current
antisens
drug
variou
stage
clinic
test
although
antisens
method
success
use
year
studi
gene
function
antisens
technolog
fail
gain
widespread
accept
gene
knockdown
tool
larg
due
extens
experiment
test
often
need
done
find
effect
target
site
within
gene
interest
fire
mello
describ
process
caenorhabd
elegan
long
dsrna
sever
hundr
base
length
caus
suppress
complementari
gene
call
process
rna
interfer
rnai
although
mechan
understood
time
rnai
actual
seen
earli
plant
phenomenon
cosuppress
plant
suspect
degrad
pathway
rnai
evolv
antivir
defens
mechan
higher
organ
antivir
defens
mechan
complex
long
dsrna
induc
interferon
secret
activ
cascad
interferonstimul
gene
isg
well
rnai
therefor
long
dsrna
use
experiment
tool
trigger
rnai
mammalian
cell
fortun
long
dsrna
mediat
suppress
directli
instead
long
dsrna
process
endoribonucleas
dicer
short
duplex
overhang
call
small
interf
si
rna
actual
effector
speci
synthet
sirna
transfect
mammalian
cell
specif
suppress
express
complementari
gene
usual
without
trigger
interferon
respons
sirna
enter
multimemb
protein
complex
call
risc
rna
induc
silenc
complex
one
strand
duplex
bpasseng
strandq
cleav
discard
strand
retain
serv
bguid
strand
q
direct
sequenc
specif
risc
therefor
rnai
silenc
compon
human
risc
identifi
assign
function
argonaut
function
bslicer
q
rna
endonucleas
cleav
target
rna
speci
direct
sirna
guid
strand
dicer
trbp
form
heterodim
process
long
dsrna
sirna
togeth
complex
sirna
form
function
silenc
complex
biochemistri
degrad
rnai
extens
studi
well
summar
recent
review
rnai
exploit
complex
natur
pathway
regul
gene
express
includ
machineri
sequencespecif
mrna
degrad
specif
sirna
design
rule
develop
studi
compar
effect
vs
ineffect
duplex
possibl
obtain
potent
rnai
reagent
without
extens
test
need
use
tradit
antisens
approach
sirna
surprisingli
potent
transfect
done
use
subnanomolar
concentr
rna
sometim
achiev
reduct
mrna
level
rnai
rapidli
adopt
research
commun
keyword
search
brnai
sirna
rna
interferenceq
find
almost
citat
alreadi
exist
pubm
databas
rnai
larg
replac
antisens
gene
knockdown
tool
choic
applic
vitro
show
similar
promis
vivo
applic
two
differ
gener
approach
use
trigger
rna
interfer
vivo
first
synthet
rna
duplex
introduc
directli
anim
rnai
effect
transient
case
dsrna
usual
chemic
synthes
problem
surround
use
parallel
encount
smallmolecul
antisens
drug
develop
altern
dsrna
express
insid
cell
use
dna
templat
direct
synthesi
rna
duplex
short
hairpin
rna
case
rnai
effect
sustain
could
theoret
perman
depend
upon
vector
employ
whether
express
level
adequ
maintain
long
term
dnadirect
rnai
ddrnai
express
cassett
introduc
anim
use
plasmid
viral
vector
problem
surround
approach
parallel
encount
form
gene
therapi
present
review
restrict
use
chemic
synthes
sirna
duplex
vivo
focu
methodolog
recent
review
consid
vivo
use
sirna
differ
perspect
number
import
issu
need
consid
embark
vivo
studi
use
rnai
includ
site
select
compound
design
chemistri
control
rout
administr
use
deliveri
vehicl
site
select
optim
appear
difficult
sirna
would
expect
histor
experi
antisens
oligonucleotid
site
select
effect
site
select
algorithm
avail
sever
commerci
academ
sourc
key
element
design
criteria
publish
undertak
vivo
experi
howev
actual
valid
duplex
vitro
perform
usual
necessari
test
small
number
duplex
possibl
three
four
find
suitabl
candid
prefer
one
effect
sirna
avail
target
help
control
offtarget
effect
see
sirna
therapeut
applic
extens
optim
cours
expect
vivo
sirna
experi
report
date
use
duplex
central
doublestrand
domain
termin
overhang
reagent
mimic
product
natur
produc
dicer
process
vivo
design
avail
may
worth
consider
blunt
duplex
extens
modif
shown
favor
properti
blunt
duplex
sensestrand
modif
also
use
good
result
asymmetr
duplex
substrat
dicer
shown
increas
potenc
vitro
compar
may
similar
benefit
vivo
although
duplex
rna
resist
nucleas
attack
singlestrand
dna
unmodifi
sirna
nevertheless
rapidli
degrad
administ
intraven
mammal
degrad
delay
avoid
chemic
modif
oligonucleotid
andor
complex
carrierdeliveri
particl
wide
varieti
chemic
modif
confer
nucleas
resist
success
use
singlestrand
antisens
oligonucleotid
ribozym
mani
modif
import
directli
sirna
use
provid
similar
benefit
phosphorothio
boranophosph
modif
internucleosid
linkag
improv
nucleas
stabil
boranophosphatemodifi
rna
substanti
nucleas
resist
unfortun
boranophosphatemodifi
rna
simpli
manufactur
use
standard
chemic
synthesi
method
instead
boranomodifi
base
incorpor
rna
made
enzymat
synthesi
use
vitro
transcript
make
siteselect
placement
modif
difficult
phosphorothio
ps
modif
easili
place
rna
duplex
desir
posit
prolong
life
duplex
expos
serum
nucleas
sourc
limit
ps
modif
preserv
potenc
sirna
howev
extens
modifi
duplex
show
reduc
potenc
andor
toxic
extens
ps
modif
also
lead
artifact
due
nonspecif
protein
bind
may
prefer
limit
use
modif
termin
posit
overhang
ad
nucleas
resist
probabl
import
nucleaseresist
modif
kind
problem
avail
modif
posit
ribos
increas
duplex
stabil
confer
vari
degre
nucleas
resist
rna
natur
occur
base
present
mammalian
ribosom
rna
number
report
describ
pattern
incorpor
retain
full
potenc
sirna
compar
unmodifi
rna
stabl
serum
precis
pattern
incorpor
import
rna
entir
substitut
inact
trigger
rnai
altern
base
retain
potenc
confer
substanti
nucleas
resist
modif
also
use
good
result
modif
usual
incorpor
select
pyrimidin
base
due
reagent
issu
use
either
alon
combin
purin
stabil
rna
duplex
fact
duplex
fulli
modifi
unmodifi
rna
remain
lock
nucleic
acid
lna
differ
class
modif
methylen
bridg
connect
ribos
modif
blocksq
ribos
conform
improv
duplex
stabil
nucleas
resist
lna
incorpor
sirna
howev
placement
achiev
best
effect
restrict
base
sever
studi
alreadi
conduct
mice
compar
function
perform
modifi
vs
unmodifi
sirna
duplex
layzer
colleagu
modifi
antiluciferas
sirna
pyrimidin
compar
unmodifi
sirna
vivo
use
hydrodynam
tail
vein
inject
sirna
coinject
luciferas
express
plasmid
luciferas
activ
liver
assess
vivo
bioluminesc
imag
day
inject
despit
improv
nucleas
stabil
function
differ
luciferas
knockdown
observ
modifi
unmodifi
sirna
use
hydrodynam
deliveri
inject
nucleic
acid
rapidli
taken
hepatocyt
thu
nucleas
resist
may
import
sirna
administ
use
approach
use
tradit
lowpressur
intraven
administr
unfortun
singl
sirna
dose
use
make
difficult
assess
potenc
accur
without
addit
data
obtain
doserespons
curv
group
report
substanti
benefit
use
highli
modifi
sirna
duplex
morrissey
colleagu
compar
activ
unmodifi
sirna
highli
modifi
duplex
includ
dna
base
purin
pyrimidin
termin
inverteddt
base
ps
linkag
modif
select
posit
leav
unmodifi
rna
hepat
b
viru
hbv
express
plasmid
coinject
modifi
unmodifi
duplex
tail
vein
mice
use
hydrodynam
deliveri
method
product
hbv
dna
hepat
b
surfac
antigen
assay
h
postinject
doserespons
curv
perform
modifi
duplex
significantli
potent
unmodifi
rna
may
suitabl
use
vivo
research
applic
especi
deliveri
vehicl
offer
protect
serum
nucleas
employ
howev
may
reason
beyond
nucleas
resist
includ
modifi
base
sirna
use
vivo
see
discuss
innat
immun
variou
chemic
group
place
end
oligonucleotid
facilit
entri
cell
improv
biodistribut
experi
modif
categori
gain
work
done
improv
properti
antisens
oligonucleotid
appli
directli
sirna
exampl
conjug
cholesterol
sirna
improv
serum
protein
bind
improv
pharmacokinet
increas
deliveri
hepatocyt
lipid
conjug
use
although
synthesi
current
complex
dinitrophenol
end
modif
shown
improv
transfect
increas
intracellular
stabil
tissu
cultur
perhap
greatest
interest
peptideoligonucleotid
conjug
improv
cell
permeat
properti
well
nuclear
target
desir
peptid
deliveri
consid
greater
detail
seem
unlik
major
advers
effect
observ
use
sirna
vivo
could
predict
prior
experi
toxicolog
antisens
oligonucleotid
ribozym
earli
result
suggest
biodistribut
sirna
grossli
similar
seen
use
singlestrand
dna
oligonucleotid
phase
clinic
trial
alreadi
ongo
inform
soon
avail
pharmacolog
sirna
human
specif
problem
alreadi
identifi
need
consid
experiment
design
inclus
appropri
control
includ
stimul
innat
immun
system
lead
interferon
pathway
cascad
offtarget
effect
ote
perhap
signific
unexpect
bside
effectq
encount
use
antisens
dna
oligonucleotid
sequencespecif
abil
trigger
innat
immun
system
properti
trace
recognit
motif
contain
nonmethyl
dc
base
context
bcpgq
dinucleotid
tolllik
receptor
although
origin
view
nuisanc
side
effect
observ
open
entir
new
therapeut
use
dna
oligonucleotid
modul
immun
system
innat
immun
system
reli
upon
seri
receptor
molecul
recogn
bpathogenassoci
molecular
patternsq
initi
varieti
cellular
respons
motif
encount
one
class
receptor
tolllik
receptor
famili
recogn
compound
rang
bacteri
lipopolysaccharid
lp
dna
long
dsrna
wellknown
trigger
interferon
ifn
respons
mammal
origin
hope
short
dsrna
like
sirna
would
bsafeq
use
howev
sirna
also
capabl
trigger
ifn
respons
effect
sequenc
specif
celltyp
specif
therefor
alway
encount
member
tolllik
receptor
famili
recogn
nucleic
acid
resid
intracellularli
within
endosom
lysosom
compart
tlr
resid
cell
surfac
known
tlr
specif
interact
rna
identifi
includ
molecul
recogn
dsrna
trigger
ifn
pathway
respons
includ
dsrnadepend
protein
kinas
pkr
synthetas
oa
retino
acidinduc
gene
rigi
sledz
colleagu
report
sirna
could
caus
interferonmedi
activ
jakstat
pathway
dosedepend
induct
isg
cell
attribut
pkr
activ
effect
appear
sequenc
independ
two
differ
sirna
share
obviou
sequenc
motif
trigger
effect
contrast
stimul
ifna
ifnh
phosphopkr
detect
administr
either
dsrna
cell
activ
dsrna
requir
minimum
rna
length
bp
maxim
activ
achiev
length
reach
bp
direct
trigger
sirna
unlik
problem
requir
rigi
activ
investig
appear
recogn
short
sirna
may
major
pathway
ifn
product
activ
isg
least
vitro
j
marqu
b
r
g
william
person
commun
rna
synthes
vitro
transcript
retain
triphosph
group
end
trigger
robust
ifn
respons
easili
avoid
use
chemic
synthes
rna
known
structur
puriti
tolllik
receptor
recogn
dsrna
certain
sirna
shown
trigger
releas
ifna
ifnh
interleukin
cell
effect
dose
depend
magnifi
overexpress
tolllik
receptor
recogn
ssrna
trigger
sirna
sequencespecif
fashion
singlestrand
rna
effect
doublestrand
rna
trigger
respons
sequenc
ugugu
guccuucaa
demonstr
stimul
secret
varieti
cytokin
cell
type
express
limit
number
cell
type
includ
myeloid
dendrit
cell
plasmacytoid
dendrit
cell
neutrophil
b
cell
monocyt
howev
cell
found
throughout
bodi
sirna
trigger
ifn
secret
human
peripher
blood
mononuclear
cell
pbmc
stimul
innat
immun
system
must
consid
use
kind
system
administr
local
intracellularli
endosom
deliveri
compart
must
take
place
activ
occur
cell
cultur
cation
lipid
transfect
agent
deliv
nucleic
acid
endosom
compart
electropor
sirna
deliveri
done
use
electropor
less
like
stimul
ifn
secret
principl
appear
appli
vivo
intraven
administr
mice
unmodifi
sirna
complex
lipid
particl
like
caus
ifn
pathway
activ
intraven
administr
unmodifi
bnakedq
sirna
use
highvolum
hydrodynam
deliveri
cation
dotap
liposom
significantli
enhanc
abil
sirna
trigger
ifn
respons
pbmc
mice
inform
sirna
activ
innat
immun
via
tlr
signal
found
recent
review
marqu
william
sequenc
capabl
activ
ifn
via
bind
identifi
better
strategi
simpli
avoid
bbadq
motif
may
need
gener
use
sirna
vivo
cell
type
present
use
chemic
modifi
rna
may
overcom
mani
problem
recent
studi
kariko
colleagu
compar
capac
rna
prokaryot
eukaryot
sourc
abil
trigger
ifn
respons
observ
prokaryot
rna
much
potent
trigger
signal
pathway
eukaryot
rna
weaker
absent
receptor
signal
eukaryot
rna
sequenc
depend
rather
due
base
andor
sugar
modif
present
nucleic
acid
much
like
reduc
prevent
activ
cpg
motif
dna
presenc
n
methyla
pseudouridin
base
prevent
recognit
rna
importantli
shown
extens
modif
sequenc
otherwis
strongli
immunostimulatori
unmodifi
rna
prevent
immun
respons
sequenc
administ
intraven
iv
mice
use
lipidbas
particl
deliveri
system
howev
might
necessari
modifi
rna
duplex
extens
block
immun
respons
judg
colleagu
report
substitut
two
base
one
strand
sirna
duplex
suffici
block
tlr
activ
vitro
human
pbmc
vivo
iv
deliveri
mice
use
stabil
nucleic
acid
lipid
particl
snalp
facilit
deliveri
modifi
u
g
base
effect
achiev
affect
sinc
select
incorpor
base
inexpens
compromis
sirna
function
activ
use
modif
duplex
intend
vivo
applic
consid
certain
sequenc
activ
stimul
innat
immun
respons
via
tlr
pathway
sequenc
inhibit
block
respons
barrat
colleagu
describ
sever
sequenc
motif
prevent
andor
activ
present
ssdna
oligonucleotid
would
also
interest
see
endosom
inhibitor
chloroquin
might
blunt
innat
immun
respons
sirna
given
sequencespecif
variat
abil
duplex
trigger
innat
immun
respons
may
imposs
ensur
singl
bneg
control
duplexq
realli
valid
control
might
therefor
judici
measur
serum
cytokin
level
routin
verifi
whether
ifn
induct
actual
occur
assist
interpret
vivo
result
even
modifi
duplex
employ
nucleic
acid
base
pair
highli
specif
mismatch
one
small
number
posit
short
sequenc
often
suffici
prevent
hybrid
complet
physiolog
condit
base
upon
antisens
oligonucleotid
experi
origin
hope
perform
genomewid
homolog
search
elimin
site
signific
crosshybrid
potenti
would
ensur
specif
sirna
gene
target
inde
even
singl
mismatch
disrupt
sirna
action
intend
target
systemat
analysi
function
impact
caus
base
chang
posit
target
site
report
use
guid
assist
sirna
design
unfortun
kind
tradit
homolog
crosshybrid
analysi
insuffici
sirna
caus
widespread
chang
express
level
seemingli
unrel
gene
rnai
mediat
multimemb
protein
complex
mechanist
repress
gene
express
differ
way
use
perfect
vs
imperfect
duplex
degrad
rnai
lead
sequencespecif
cleavag
target
mrna
direct
risc
use
initi
event
requir
perfect
nearperfect
base
pair
sirnaderiv
guid
strand
convers
microrna
mirna
pathway
result
translat
repress
direct
imperfect
base
pair
target
guid
strand
pathway
theoriz
mediat
variant
risc
use
function
sirna
degrad
pathway
mirna
translat
repress
pathway
overlap
exogen
suppli
sirna
duplex
function
mirna
mirna
direct
target
cleavag
event
seem
like
mani
ote
attribut
sirna
deriv
mirnalik
target
interact
trigger
surprisingli
limit
sequenc
homolog
target
specif
mirna
larg
direct
bseed
regionq
end
antisens
strand
mirna
unfortun
even
small
amount
homolog
give
rise
ote
lin
colleagu
report
result
largescal
sirna
librari
screen
top
three
bhitsq
deriv
offtarget
event
two
event
result
complement
sirna
boff
targetq
given
expect
frequenc
find
match
sirna
nontarget
gene
within
entir
transcriptom
mammal
simpl
homolog
screen
alon
insuffici
predict
elimin
offtarget
event
possibl
pattern
chemic
modif
decreas
abil
sirna
particip
class
ote
use
sirna
research
tool
simpl
strategi
help
ensur
result
misinterpret
unsuspect
ote
requir
two
independ
sirna
target
produc
biolog
result
develop
sirna
therapeut
agent
extens
test
may
need
ensur
potenti
drug
candid
accept
degre
ote
clear
metric
employ
assess
ote
vivo
microarray
employ
document
chang
gene
express
profil
result
sirna
treatment
genomewid
scale
vitro
studi
yet
report
kind
experi
vivo
regul
bunrelatedq
gene
might
might
result
biolog
signific
advers
event
vivo
tradit
badvers
eventq
assess
routin
perform
smallmolecul
drug
develop
program
may
relev
method
consid
unwant
affect
sirna
drug
without
need
addit
studi
catalog
presenc
absenc
bunintend
gene
regul
eventsq
cellular
machineri
respons
degrad
rna
interfer
also
particip
process
mirna
microrna
import
cellular
gene
regul
network
anyth
disrupt
alter
mirna
process
could
potenti
broad
affect
gene
express
cell
theoret
possibl
high
dose
exogen
sirna
administ
therapeut
investig
tool
could
bsaturateq
rnai
machineri
therebi
alter
mirna
level
complic
spectrum
ote
hong
colleagu
describ
high
dose
sirna
induc
express
gene
involv
sirna
degrad
process
stimul
ifn
pathway
ote
desir
gene
knockdown
dose
depend
precis
dose
need
trigger
respons
differ
may
possibl
influenc
rel
magnitud
undesir
side
effect
care
attent
dose
doserespons
profil
perform
vivo
sirna
regent
subsequ
administ
lowest
level
achiev
desir
degre
target
knockdown
therapeut
effect
rout
sirna
administr
affect
total
dose
need
effect
tissu
distribut
potenti
side
effect
need
chemic
modif
use
agent
facilit
deliveri
although
iv
administr
often
consid
broadest
tissu
distribut
import
consid
altern
inject
site
intraperiton
ip
subcutan
sc
rout
local
deliveri
use
achiev
high
concentr
intend
target
site
use
low
dose
minim
risk
system
side
effect
local
deliveri
achiev
direct
inject
tumor
joint
intraocularli
topic
applic
surfac
transepitheli
absorpt
oral
rectal
vagin
mucosa
direct
administr
central
nervou
system
cn
achiev
intrathec
intraventricular
inject
bypass
issu
bloodbrain
barrier
penetr
inhal
intranas
intratrach
administr
employ
pulmonari
deliveri
although
report
life
span
unmodifi
sirna
serum
vari
minut
day
obviou
chemic
modifi
duplex
surviv
longer
nucleaserich
environ
unmodifi
rna
even
chemic
modif
employ
stabil
duplex
degrad
plasma
clearanc
may
still
rapid
use
deliveri
vehicl
improv
pharmacokinet
morrissey
colleagu
report
plasma
halflif
unmodifi
sirna
duplex
mice
h
halflif
modifi
duplex
h
halflif
modifi
duplex
packag
snalp
h
similarli
soutschek
colleagu
report
studi
use
modifi
sirna
rat
unconjug
duplex
elimin
halflif
h
cholesterolconjug
duplex
halflif
h
may
reason
employ
unmodifi
duplex
basic
research
applic
vivo
sustain
effect
potenti
therapeut
benefit
achiev
use
chemic
modifi
duplex
togeth
kind
deliveri
system
wide
varieti
method
use
facilit
deliveri
nucleic
acid
nucleic
acid
high
neg
charg
densiti
cation
polym
usual
employ
bind
nucleic
acid
neutral
charg
assist
transport
across
cell
membran
cation
lipid
routin
use
great
success
transfect
agent
tissu
cultur
howev
vivo
use
iv
administr
present
signific
problem
reagent
quit
toxic
despit
problem
iv
use
cation
lipid
sometim
employ
ip
inject
cn
inject
topic
epitheli
surfac
applic
toxic
vari
precis
chemic
composit
lipid
employ
dose
varieti
factor
variat
chemic
composit
larg
impact
function
properti
cation
lipid
mixtur
lipoplexliposom
prepar
devis
decreas
toxic
compat
iv
administr
liposom
formul
fda
approv
smallmolecul
drug
deliveri
sinc
late
liposom
modifi
ligand
folat
small
peptid
assist
deliveri
help
target
specif
cell
type
tissu
use
neutral
polyethylen
glycolsubstitut
surfac
approach
liposom
stabil
made
bstealthi
q
show
reduc
clearanc
improv
pharmacokinet
kind
lipid
nanoparticl
success
use
deliv
antisens
oligonucleotid
sirna
vivo
polyethylenimin
pei
use
mani
year
facilit
nucleic
acid
deliveri
howev
due
toxic
variabl
perform
found
gener
accept
deliveri
tool
either
antisens
oligonucleotid
sirna
nevertheless
pei
use
bbaseq
formul
complex
particl
improv
properti
exampl
pegyl
pei
particl
vasculaturetarget
rdg
peptid
shown
deliv
sirna
success
mous
xenograft
tumor
model
deacyl
pei
lower
toxic
improv
pulmonari
deliveri
sirna
mice
folatemodifi
pegyl
pei
test
sirna
deliveri
tumor
cell
cyclodextrinmodifi
pei
favor
properti
nucleic
acid
deliveri
compar
unmodifi
pei
cyclodextrin
polym
cdp
rel
low
toxic
addit
adamantinepeg
spontan
form
stabl
particl
nucleic
acid
cargo
physiolog
condit
peibas
cdp
shown
function
vivo
deliveri
nucleic
acid
cdp
synthes
use
polyc
pei
option
includ
termin
imidazol
group
improv
endosom
traffick
conjug
transferrin
linear
cyclodextrincontain
polymeradamantinepeg
complex
improv
tumor
target
vivo
kind
polyplex
shown
effect
deliv
sirna
mice
gener
strategi
transferrinconjug
polyc
shown
facilit
transfect
dna
year
ago
varieti
differ
conjug
facilit
deliveri
nucleic
acid
character
novel
smallmolecul
librari
develop
assist
target
differ
cell
type
may
eventu
offer
bmenuq
enabl
select
deliveri
therapeut
compound
wherev
desir
polyc
complex
sirna
facilit
deliveri
protamin
employ
carrier
nucleic
acid
conjug
varieti
molecul
improv
perform
includ
lipid
protamin
conjug
antibodi
fab
fragment
target
deliveri
select
specif
cell
type
approach
success
use
deliv
sirna
mice
cation
peptid
also
use
facilit
nucleic
acid
entri
cell
exploit
capabl
certain
sequenc
enter
cell
directli
cellpenetr
peptid
enter
specif
cell
type
select
celltarget
peptid
peptid
mpg
penetratin
transportin
shown
promot
deliveri
sirna
tissu
cultur
may
promis
vivo
use
gener
peptid
carrier
effect
also
exploit
atelocollagen
purifi
pepsin
digest
collagen
shown
function
deliveri
vehicl
sirna
mice
dnapackag
motor
bacteriophag
conjug
sirna
shown
facilit
cell
entri
modifi
viru
envelop
adapt
deliv
nucleic
acid
cell
fusogen
influenza
viru
envelop
use
deliv
fluoresc
dyelabel
sirna
ip
inject
mice
hemagglutin
viru
japan
envelop
use
deliv
sirna
via
direct
intratumor
inject
mice
pseudovirion
test
deliveri
vehicl
potenti
antigen
deliveri
tool
need
address
consider
therapeut
applic
physic
mechan
deliveri
method
also
consid
fact
singl
commonli
employ
strategi
vivo
sirna
deliveri
date
bhydrodynam
deliveryq
hd
method
approach
larg
volum
nucleic
acid
solut
rapidli
inject
tail
vein
mous
transient
disrupt
vascular
tissu
integr
achiev
deliveri
morbid
signific
success
use
method
techniqu
depend
nevertheless
hd
use
research
tool
especi
effect
deliv
nucleic
acid
liver
recent
report
also
demonstr
success
use
electropor
ultrasound
particlebas
bgene
gunq
deliveri
system
although
larg
number
studi
report
success
vivo
deliveri
nucleic
acid
use
liposom
polyplex
reagent
issu
toxic
remain
must
consid
chien
colleagu
compar
toxic
iv
inject
cation
dotap
liposom
directli
cardiolipin
analogu
ccla
dope
liposom
mice
part
evalu
use
deliveri
system
sirna
liposom
administ
tail
vein
inject
mice
follow
week
two
three
mice
given
singl
dose
mgkg
dotap
liposom
die
compar
mice
given
ccla
liposom
ccla
liposom
also
studi
multipl
dose
regimen
mice
receiv
mgkgday
consecut
day
die
anim
may
surviv
yet
still
suffer
deliveryrel
morbid
affect
experiment
result
must
consid
much
toxic
cation
lipid
relat
electrostat
effect
precis
complex
ratio
posit
charg
lipid
neg
charg
cargo
nucleic
acid
import
interact
neg
charg
serum
protein
inactiv
complex
particl
aggreg
clump
capillari
bed
problemat
interact
complement
protein
lead
inflamm
load
nucleic
acid
cargo
cation
lipid
trigger
releas
varieti
cytokin
see
discuss
tlr
activ
lymphopenia
thrombocytopenia
hepat
necrosi
occur
higher
dose
lipid
newer
class
lipidnucl
acid
deliveri
system
fulli
encapsul
complex
nucleic
acid
cargo
present
stabil
neutral
surfac
intravascular
environ
lower
toxic
improv
stabil
prolong
serum
circul
time
recent
review
dass
audouy
simberg
provid
greater
detail
cation
liposom
deliveri
method
vivo
toxic
polyplex
deliveri
system
similar
toxic
problem
ld
linear
pei
around
mgkg
mice
significantli
limit
vivo
util
cyclodextrin
polym
much
less
toxic
ld
mgkg
mice
graft
hcyclodextrin
onto
pei
reduc
toxic
also
decreas
effici
nucleic
acid
transfect
care
optim
need
addit
adamantinepeg
form
inclus
complex
coat
complex
way
stabil
polymernucl
acid
particl
physiolog
salt
condit
without
increas
size
help
lower
toxic
transferrin
ligand
ad
polym
help
celltyp
target
overview
issu
involv
polyplex
design
see
recent
review
davi
colleagu
also
possibl
perform
vivo
gene
knockdown
experi
use
ex
vivo
deliveri
method
avoid
potenti
complic
andor
toxic
associ
variou
vivo
deliveri
method
cell
line
transfect
sirna
tissu
cultur
use
standard
method
subsequ
implant
recipi
anim
chang
phenotyp
behavior
vivo
studi
avoid
challeng
associ
tradit
vivo
deliveri
exampl
one
studi
employ
ex
vivo
method
human
melanoma
tumor
cell
transfect
cultur
use
electropor
either
control
sirna
sirna
specif
mutant
braf
gene
studi
bstealthq
sirna
employ
chemic
modifi
blunt
duplex
select
incorpor
rna
sens
strand
transfect
cell
implant
nude
mice
cell
transfect
control
sirna
day
develop
tumor
foci
wherea
cell
transfect
anti
braf
sirna
took
day
develop
mm
tumor
foci
report
involv
vivo
administr
sirna
mammal
publish
follow
survey
studi
focu
methodolog
employ
rout
administr
use
deliveri
vehicl
use
chemic
modifi
duplex
control
ote
ifn
induct
tabl
includ
list
studi
organ
bsystemq
studi
select
studi
examin
greater
detail
organ
rout
administr
first
publish
report
vivo
use
sirna
mammal
appear
mccaffrey
colleagu
use
hd
deliveri
introduc
ag
luciferas
express
plasmid
ag
unmodifi
control
antiluciferas
sirna
mice
human
antitrypsin
haat
express
plasmid
coinject
serum
level
haat
use
normal
anim
luciferas
activ
liver
assess
vivo
bioluminesc
imag
day
inject
antiluciferas
sirna
found
specif
reduc
light
emiss
ifn
level
cytokin
measur
howev
use
haat
marker
serv
control
nonspecif
effect
similar
result
use
hd
deliveri
suppress
luciferas
mice
report
lewi
colleagu
case
rnai
activ
demonstr
occur
multipl
tissu
type
includ
liver
kidney
spleen
lung
pancrea
durat
silenc
investig
use
express
plasmid
encod
secret
human
placent
alkalin
phosphatas
seap
ten
microgram
pseap
plasmid
ag
antiseap
sirna
administ
hd
inject
seap
level
suppress
day
postinject
day
control
level
day
possibl
sooner
intermedi
time
point
report
song
colleagu
report
use
sirna
protect
mice
liver
damag
two
model
system
involv
fasmedi
apoptosi
antifa
sirna
control
antiegfp
sirna
ag
ml
pb
administ
use
hd
deliveri
three
dose
fa
mrna
fa
protein
level
shown
specif
reduc
dehydrogenas
gapdh
ratio
recipi
mous
hepatocyt
rel
control
suppress
day
mice
treat
antifa
sirna
develop
fulmin
hepat
hepat
fibrosi
treatment
concanavalin
induc
hepat
treatment
antifa
sirna
also
protect
treatment
agonist
antifa
antibodi
normal
fatal
within
day
inject
similar
benefici
effect
report
use
antifa
sirna
protect
mice
renal
ischemiareperfus
injuri
sirna
administ
hd
deliveri
via
tail
vein
ag
ml
pb
lowpressur
inject
directli
renal
vein
one
seri
experi
renal
ischemia
induc
clamp
one
renal
pedicl
min
kidney
remov
surviv
significantli
higher
mice
treat
antifa
sirna
control
sirna
salin
caspas
critic
enzym
fa
apoptosi
pathway
zender
colleagu
report
use
sirna
target
caspas
block
hepat
necrosi
follow
challeng
agonist
antifa
antibodi
recombin
adenoviru
encod
fa
ligand
sirna
administ
use
hd
tail
vein
inject
dose
nmolg
mgkg
ag
per
dose
per
mous
nmol
infus
directli
portal
vein
caspas
mrna
level
reduc
fourfold
caspas
ratio
follow
sirna
treatment
mous
hepatocyt
follow
administr
fasagonist
antibodi
mice
treat
anticaspas
sirna
surviv
control
anim
surviv
use
strategi
similar
discuss
previous
protect
fasinduc
renal
ischemiareperfus
injuri
contrera
colleagu
report
success
use
anticaspas
anticaspas
sirna
protect
mice
hepat
ischemiareperfus
injuri
variant
hd
deliveri
employ
low
dose
nmol
ag
sirna
administ
ml
volum
directli
portal
vein
sirna
administ
h
injuri
hepat
blood
suppli
clamp
min
hepat
caspas
level
assay
h
reperfus
caspas
enzym
strongli
induc
ischemia
howev
rel
level
induct
reduc
approxim
twofold
sirna
treatment
one
arm
studi
mice
observ
day
ischem
injuri
liver
without
sirna
pretreat
mice
treat
anticaspas
show
surviv
mice
treat
anticaspas
show
surviv
control
mice
show
surviv
control
sirna
surviv
vehicl
hydrodynam
deliveri
also
use
studi
antivir
potenti
sirna
vivo
giladi
colleagu
demonstr
plasmid
encod
hepat
b
viru
hbv
genom
codeliv
sirna
liver
mice
use
hd
method
studi
effect
antihbv
sirna
viral
replic
five
hbv
sirna
test
surprisingli
show
differ
function
potenc
potent
reagent
capabl
reduc
hbv
titer
produc
transfect
liver
day
day
dose
studi
ag
hbv
plasmid
nmol
ag
sirna
morrissey
colleagu
employ
similar
hbv
plasmid
model
system
studi
use
antihbv
sirna
mice
also
use
hd
deliveri
compar
perform
modifi
vs
unmodifi
rna
modifi
duplex
call
bsmall
interf
nucleic
acid
sina
perform
better
show
greater
reduct
hbv
dna
surfac
antigen
level
h
postinject
sequenc
administ
unmodifi
sirna
importantli
modifi
duplex
suppress
hbv
treatment
start
day
binfectionq
via
deliveri
hbv
plasmid
hd
inject
howev
significantli
higher
dose
need
set
mgkg
although
hd
larg
view
research
tool
hagstrom
colleagu
report
success
use
method
deliv
sirna
nucleic
acid
skelet
muscl
rat
dog
rhesu
macaqu
variant
hd
method
limb
function
isol
applic
blood
pressur
cuff
tourniquet
largevolum
bolu
nucleic
acid
solut
administ
intraven
therapeut
deliveri
plasmid
sirna
human
use
approach
propos
care
taken
techniqu
moder
revers
tissu
damag
observ
despit
rel
suscept
unmodifi
sirna
duplex
degrad
serum
sever
group
report
posit
result
use
unmodifi
sirna
administ
lowvolum
intraven
inject
mice
without
use
facilit
deliveri
system
filleur
colleagu
administ
unmodifi
sirna
target
vascular
endotheli
growth
factor
vegf
nude
mice
bear
subcutan
implant
rat
fibrosarcoma
cell
express
luciferas
sirna
inject
iv
ip
sc
dose
ag
per
inject
agkgday
pb
anim
given
singl
antivegf
sirna
three
rout
show
suppress
luciferas
activ
tumor
implant
day
postinject
compar
anim
receiv
control
sirna
anim
given
daili
ip
inject
sirna
pb
day
receiv
antivegf
treatment
show
reduct
tumor
volum
reduct
tumorassoci
vegf
level
compar
control
duxburi
colleagu
studi
effect
chang
level
ribonucleotid
reductas
rr
efficaci
gemcitabin
treatment
pancreat
tumor
cell
implant
nude
mice
high
level
rr
believ
one
caus
resist
gemcitabin
chemotherapi
rr
level
reduc
use
sirna
target
subunit
rr
treatment
increas
tumor
cell
suscept
gemcitabin
vitro
pancreat
tumor
cell
implant
nude
mice
given
control
treatment
sirna
agkg
iv
andor
gemcitabin
mg
ip
twice
weekli
week
mice
treat
sirna
show
reduc
level
tumor
extract
western
blot
compar
control
sirnatr
mice
treatment
gemcitabin
sirna
alon
result
modest
reduct
tumor
volum
treatment
combin
gemcitabin
sirna
show
synergist
effect
reduct
tumor
size
mice
receiv
combin
treatment
detect
liver
metastasi
wherea
control
gemcitabin
sirna
monotherapi
anim
signific
tumor
burden
liver
group
continu
investig
use
sirna
therapi
pancreat
adenocarcinoma
use
differ
target
cellsurfac
adhes
molecul
thought
play
role
tumor
progress
metastasi
unmodifi
sirna
administ
dose
agkg
pb
iv
via
tail
vein
twice
weekli
cell
implant
pancrea
nude
mice
anim
given
pb
alon
control
sirna
sirna
week
mice
treat
targetspecif
sirna
smaller
tumor
lower
level
reduc
evid
angiogenesi
structur
use
immunohistochem
stain
reduc
hepat
metastasi
compar
control
mice
surviv
week
treatment
pbstreat
mice
control
sirnatr
mice
mice
varieti
deliveri
system
success
use
improv
sirna
uptak
follow
iv
inject
includ
liposom
polymerbas
nanoparticl
peptid
antibodi
small
molecul
ligand
soutschek
colleagu
describ
use
cholesterolconjug
sirna
reduc
express
apolipoprotein
b
apob
mice
assess
impact
serum
cholesterol
lipoprotein
particl
level
duplex
chemic
modifi
select
incorpor
rna
base
phosphorothio
linkag
cholesterol
modif
increas
serum
halflif
compar
unconjug
sirna
follow
iv
inject
sirna
level
present
variou
tissu
measur
use
sensit
rnase
protect
assay
rpa
modifi
conjug
rna
duplex
detect
sirna
seen
liver
heart
kidney
adipos
lung
tissu
extens
sequenc
optim
perform
sirna
screen
vitro
best
candid
use
vivo
mice
receiv
antiapob
sirna
control
sirna
dose
mgkg
iv
daili
day
cholesterol
level
measur
h
last
dose
protein
level
reduc
sirna
sirna
potent
sirna
show
reduct
total
serum
cholesterol
although
ifn
cytokin
measur
directli
assess
activ
innat
immun
system
mrna
level
three
unrel
control
gene
found
unaffect
sirna
treatment
mechan
action
demonstr
vivo
use
procedur
apob
speci
identifi
cleavag
point
exactli
site
predict
use
sirna
bp
end
antisens
strand
sirna
inform
compar
dose
need
achiev
physiolog
effect
sirna
sequenc
deliv
use
liposom
polymerbas
deliveri
system
judg
colleagu
administ
sirna
sequenc
discuss
mice
intraven
use
lipidbas
deliveri
vehicl
snalp
sirna
cholesterol
conjug
differ
modif
pattern
compar
employ
soutschek
limit
five
residu
substitut
sens
strand
reduct
serum
cholesterol
achiev
use
dose
mgkgday
day
dose
use
previous
cholesterolmodifi
antiapob
sirna
use
tradit
antisens
approach
crook
colleagu
report
ip
administr
bgapmerq
phosphorothio
oligonucleotid
specif
apob
reduc
total
cholesterol
similar
degre
mice
given
dose
mgkg
twice
weekli
week
dose
increas
mgkg
synthet
cardiolipin
analogu
ccla
use
make
new
famili
cation
liposom
use
iv
administr
sirna
chien
colleagu
describ
use
ccla
liposom
deliv
sirna
tail
vein
inject
mice
deliveri
effici
estim
approxim
sevenfold
better
tradit
dotap
liposom
lower
toxic
rasrafmapk
signal
pathway
thought
import
around
human
cancer
unmodifi
sirna
specif
craf
administ
via
tail
vein
dose
mgkg
twice
day
day
scid
mice
bear
sc
implant
breast
cancer
tumor
tumor
mice
treat
nake
sirna
grew
rate
control
tumor
mice
treat
liposomalsirna
smaller
day
suggest
deliveri
vehicl
signific
impact
therapeut
efficaci
anticraf
sirna
treatment
similar
seri
experi
studi
effect
sirna
without
chemotherapi
agent
taxoter
suppress
growth
sc
implant
prostat
cancer
cell
line
scid
mice
mice
administ
unmodifi
sirna
dose
mgkg
twice
day
day
either
nake
complex
ccla
liposom
without
coadministr
taxoter
mgkg
day
mgkg
day
tumor
excis
western
blot
perform
examin
protein
level
rel
control
sirna
administr
free
sirna
reduc
protein
level
ratio
liposom
sirna
reduc
level
combin
liposom
sirna
taxoter
reduc
level
nake
sirna
effect
tumor
growth
liposom
sirna
inhibit
tumor
growth
combin
taxoter
inhibit
tumor
growth
use
neutral
liposom
made
dopc
deliv
sirna
iv
mice
describ
landen
colleagu
dyelabel
rna
duplex
inject
mice
iv
use
nake
dotap
liposom
dopc
liposom
deliveri
compar
use
fluoresc
microscopi
dopc
liposom
gave
estim
improv
deliveri
compar
dotap
liposom
improv
deliveri
compar
nake
rna
greatest
uptak
sirna
seen
liver
kidney
lung
tyrosin
kinas
receptor
overexpress
human
cancer
associ
poor
outcom
ovarian
cancer
nude
mice
ip
implant
ovarian
cancer
cell
line
given
control
sirna
agkg
iv
twice
weekli
dopc
liposom
week
without
chemotherapeut
agent
paclitaxel
ag
ip
weekli
compar
mice
receiv
control
sirna
averag
tumor
size
reduc
use
sirna
use
paclitaxel
combin
therapi
sever
studi
report
similar
observ
combin
sirna
cytotox
chemotherapeut
agent
work
addit
synergist
reduc
tumor
size
also
worth
note
low
dose
sirna
employ
studi
presum
due
improv
deliveri
use
neutral
liposom
carrier
differ
type
lipid
particl
employ
morrissey
colleagu
deliv
antihbv
sirna
mous
hepat
b
model
system
particl
call
snalp
contain
cation
neutral
fusogen
lipid
fulli
encapsul
nucleic
acid
cargo
earlier
version
particl
report
improv
deliveri
phosphorothio
antisens
oligonucleotid
mice
unmodifi
highli
modifi
sirna
includ
dna
ps
bond
test
morrissey
unmodifi
sirna
administ
use
deliveri
method
strongli
stimul
innat
immun
respons
highli
modifi
duplex
deliveri
fluoresc
sirna
examin
use
snalp
result
highest
level
rna
liver
spleen
show
littl
accumul
lung
plasma
halflif
modifi
sina
snalp
h
compar
min
unmodifi
nake
sirna
hepat
binfectionq
initi
hd
deliveri
ag
pwtd
hbv
plasmid
sirna
therapi
start
day
later
mice
receiv
control
antihbv
sirna
snalp
dose
mgkgday
day
serum
hbv
dna
level
drop
log
higher
dose
reduct
hbv
dna
level
persist
week
last
sina
dose
effect
reduct
hbv
dna
achiev
use
mgkg
dose
snalp
compar
mgkg
sequenc
administ
use
hd
deliveri
nonliposom
compound
develop
deliv
nucleic
acid
vivo
form
bnanoparticl
drug
deliveri
complexq
typic
kind
compound
includ
cation
polym
bind
dna
rna
cargo
pei
neutral
bstealthq
coat
peg
target
ligand
transferrin
schiffel
colleagu
describ
use
bsteric
stabil
nanoparticleq
deliv
unmodifi
sirna
neuroblastoma
tumor
nude
mice
particl
contain
pei
bpq
nanoparticl
pei
peg
bppq
nanoparticl
pei
peg
plu
argglyasp
rgd
peptid
promot
vascular
target
brppq
nanoparticl
complex
format
sirna
particl
nanoplex
protect
unmodifi
sirna
degrad
serum
alter
vivo
deliveri
pattern
fluorescencelabel
nake
sirna
accumul
tumor
lung
liver
mostli
degrad
andor
excret
urin
fluorescencelabel
p
nanoplex
accumul
lung
liver
tumor
label
rpp
nanoplex
improv
uptak
select
tumor
mass
distribut
pp
nanoplex
report
sirna
duplex
specif
murin
vascular
endotheli
growth
factor
administ
mice
bear
tumor
dose
ag
iv
everi
day
three
cycl
treatment
mice
receiv
sirna
rpp
nanoplex
show
inhibit
tumor
growth
compar
vehicleonli
control
sirnatr
mice
newer
formul
particl
may
even
greater
potenti
sirna
drug
develop
devis
anoth
novel
particl
employ
linear
cyclodextrincontain
polym
stabil
adamantinepeg
shown
deliv
small
molecul
drug
well
nucleic
acid
vivo
cyclodextrinpolyc
bpolyplexq
conjug
transferrin
improv
uptak
tumor
cell
use
deliv
unmodifi
sirna
mous
model
ewe
sarcoma
mani
ewe
sarcoma
tumor
contain
transloc
result
product
aberr
transcript
thought
function
oncogen
transcript
factor
sirna
control
sirna
administ
scid
mice
bear
tumor
form
cell
stabli
express
luciferas
enabl
bioluminesc
imag
tumor
implant
administr
day
use
transferrin
polyplex
dose
ag
mgkgday
result
transient
suppress
luciferas
signal
reduct
mrna
level
normal
hactin
establish
tumor
anoth
seri
experi
sirna
administr
start
concurr
inject
tumor
cell
mice
follow
week
twice
weekli
dose
mgkg
sirna
mice
receiv
control
sirna
form
receiv
nake
rapid
tumor
develop
mice
receiv
nontarget
polyplex
delay
onset
tumor
receiv
deliv
transferrin
polyplex
minim
tumor
format
ogri
colleagu
describ
use
transferrin
epiderm
growth
factor
ligand
improv
target
dna
polyplex
pegyl
pei
tumor
cell
mice
employ
kind
specif
cellsurfac
marker
receptor
target
techniqu
seem
gener
improv
vivo
deliveri
nucleic
acid
polyplex
antibodi
high
specif
varieti
wellcharacter
reagent
avail
boff
shelfq
recogn
mani
differ
mous
human
cell
surfac
marker
song
colleagu
describ
method
protamin
conjug
cterminu
antibodi
fab
fragment
use
cellmarkerspecif
reagent
deliv
unmodifi
sirna
mice
one
seri
experi
fab
fragment
specif
hiv
envelop
glycoprotein
coupl
protamin
six
sirna
form
deliveri
complex
one
carrier
complex
effect
deliv
sirna
cell
type
test
express
hiv
env
gene
even
cell
notori
difficult
transfect
administr
sirna
use
carrier
elicit
immun
respons
melanoma
cell
vitro
hifn
mrna
level
assay
use
qrtpcr
cell
compet
tlr
respons
express
may
worthwhil
determin
method
deliveri
trigger
innat
immun
respons
myeloid
dendrit
cell
line
vivo
murin
cell
implant
mice
differ
sirna
administ
iv
without
carrier
fluoresc
dyelabel
control
sirna
use
assess
specif
deliveri
nake
sirna
enter
tumor
cell
use
carrier
tumor
show
high
uptak
dyelabel
sirna
wherea
nativ
tumor
demonstr
specif
deliveri
method
tumor
cell
inject
flank
recipi
mice
cocktail
three
sirna
specif
cmyc
vegf
administ
either
iv
direct
tumor
inject
without
carrier
day
dose
ag
mgkg
tumor
remov
day
intratumor
iv
administr
sirna
cocktail
deliveri
significantli
reduc
tumor
size
wherea
nake
sirna
control
treatment
effect
although
complic
polyplex
deliveri
system
offer
signific
advantag
administr
sirna
vivo
simpl
cation
polym
also
use
success
ge
colleagu
report
use
pei
deliv
sirna
target
influenza
viru
via
retroorbit
iv
inject
mice
unmodifi
sirna
specif
gene
encod
nucleocapsid
protein
np
viral
transcriptas
pa
administ
dose
ag
iv
complex
pei
al
pb
use
nitrogen
phosphoru
ratio
treatment
trigger
obviou
innat
immun
respons
ifna
detect
lung
mice
use
either
influenza
control
sirna
pei
administr
either
influenzaspecif
sirna
reduc
viral
titer
infect
mous
lung
combin
antinp
antipa
sirna
effect
reduct
viral
titer
rang
log
seen
sirna
treatment
effect
even
given
h
infect
thoma
colleagu
report
deacyl
pei
improv
deliveri
plasmid
dna
mice
iv
administr
fold
dramat
improv
pulmonari
target
deacyl
use
deliv
antinp
sirna
mice
retroorbit
iv
inject
use
vivo
influenza
model
system
describ
ge
reduct
viral
titer
achiev
administr
singl
dose
sirna
howev
result
similar
report
previous
ge
use
similar
sirna
dose
unalt
pei
atelocollagen
peptic
digest
collagen
low
immunogen
takeshita
colleagu
report
use
atelocollagen
assist
iv
deliveri
sirna
bone
tumor
metastasi
model
system
mice
luciferaseexpress
cell
inject
nude
mice
week
unmodifi
sirna
administ
dose
ag
mgkg
iv
inject
either
without
atelocollagen
luciferas
express
measur
vivo
bioluminesc
h
later
control
sirna
nake
antiluc
sirna
effect
antiluc
sirna
administ
atelocollagen
show
reduct
luciferas
light
emiss
tissu
distribut
sirna
assess
use
rpa
atelocollagen
seen
facilit
deliveri
liver
lung
spleen
kidney
innat
immun
stimul
test
h
postinject
sirna
deliv
approach
result
detect
increas
ifna
level
howev
singl
time
point
examin
may
inadequ
support
conclus
fulli
two
gene
thought
involv
metastasi
target
enhanc
zest
homolog
sirna
administ
iv
dose
ag
day
inject
tumor
cell
anim
imag
presenc
bone
implant
use
control
nake
sirna
effect
tumor
develop
howev
sirna
gave
dramat
reduct
number
bone
lesion
administ
atelocollagen
although
research
report
success
use
unmodifi
sirna
nake
iv
administr
number
studi
report
improv
uptak
efficaci
seen
sirna
administ
complex
kind
polym
facilit
deliveri
andor
tissu
target
inject
bacteri
lp
mice
trigger
secret
tumor
necrosi
factor
tnfa
cytokin
macrophag
result
septic
shocklik
syndrom
death
cardiovascular
collaps
sorenson
colleagu
describ
use
unmodifi
antitnf
sirna
rescu
mice
would
otherwis
fatal
dose
lp
mice
given
antitnf
sirna
cation
dotap
liposom
ip
inject
dose
state
h
administr
ag
bacteri
lp
mice
given
mismatch
control
sirna
bsurvivedq
treatment
mice
given
antitnf
sirna
bsurvivedq
precis
mean
bsurvivalq
experi
howev
entir
clear
sinc
mice
euthan
base
subject
evalu
morbid
cytokin
level
measur
periton
lavag
fluid
tnfa
reduc
antitnftr
anim
level
unchang
yin
colleagu
use
ip
deliveri
sirna
cation
lipid
studi
role
heatshock
protein
hsp
thermotoler
cardiac
ischemiareperfus
injuri
mice
unmodifi
sirna
target
heat
shock
factor
given
dose
ag
mgkg
ip
inject
cation
lipid
h
sirna
inject
mice
subject
wholebodi
hyperthermia
wbh
elev
rectal
temperatur
min
cardiac
ischemiareperfus
injuri
perform
h
wbh
treatment
usual
induc
fourfold
control
level
wbh
treatment
sirna
block
elev
mrna
ratio
rel
aminealon
control
control
sirna
treatment
sirna
result
increas
size
myocardi
infarct
follow
ischem
injuri
increas
mortal
wbh
would
expect
protect
effect
hsp
remov
sirna
treatment
urbanklein
colleagu
use
linear
lowmolecularweight
pei
carrier
deliv
unmodifi
sirna
ip
administr
nude
mice
sc
implant
tumor
abil
pei
protect
unmodifi
sirna
degrad
serum
examin
nake
sirna
degrad
within
min
exposur
serum
sirna
complex
pei
intact
h
intraperiton
administr
sirnapei
led
highest
accumul
muscl
tumor
lesser
extent
liver
tumor
implant
flank
nude
mice
sirna
specif
oncogen
administ
three
time
week
dose
nmol
ag
start
tumor
reach
size
mm
control
nake
sirna
influenc
tumor
growth
sirna
administ
pei
led
mark
reduct
tumor
size
well
averag
reduct
mrna
excis
tumor
direct
inject
sirna
target
tissu
allow
lower
dose
rel
system
administr
reduc
risk
system
toxic
permit
access
otherwis
protect
site
cn
interior
eye
mention
previous
fdaapprov
antisens
drug
vitraven
given
intraocular
inject
treat
cmv
retin
intraocular
inject
therefor
obviou
approach
vivo
use
sirna
research
applic
pharmaceut
develop
reich
colleagu
describ
use
unmodifi
sirna
administ
intraocular
inject
inhibit
neovascular
follow
laser
photocoagul
demonstr
feasibl
method
recombin
adenoviru
express
enhanc
green
fluoresc
protein
egfp
inject
subretin
eye
mice
without
pmol
ag
antiegfp
sirna
retina
examin
h
antiegfp
sirna
almost
total
elimin
egfp
fluoresc
even
use
low
dose
administr
similar
low
dose
antivegf
sirna
reduc
area
choroid
neovascular
laser
photocoagul
injuri
shen
colleagu
also
report
use
sirna
disrupt
vegf
pathway
reduc
neovascular
follow
laser
photocoagul
mice
compound
studi
chemic
modifi
sirna
target
develop
therapeut
treatment
agerel
macular
degener
see
sirna
administ
direct
intravitr
inject
dose
ag
al
pb
day
follow
laserinduc
ruptur
bruch
membran
day
choroid
neovascular
visual
use
fluoresceinlabel
dextran
fluoresc
microscopi
neovascular
reduc
use
dose
compar
inject
control
sirna
eye
use
dose
compar
inject
pb
alon
dose
ag
given
periocular
inject
less
traumat
method
administr
day
result
reduct
neovascular
follow
laser
treatment
treatment
also
protect
oxygeninduc
ischem
retinopathi
mrna
protein
demonstr
specif
reduc
inject
distribut
brdulabel
sirna
intravitr
inject
studi
h
label
sirna
detect
ganglion
cell
h
sirna
present
ganglion
cell
inner
nuclear
layer
h
stain
absent
ganglion
cell
increas
photoreceptor
cell
bodi
inject
sirna
longer
detect
day
postinject
ocular
infect
herp
simplex
viru
hsv
induc
stromal
kerat
neovascular
kim
colleagu
use
unmodifi
sirna
target
three
gene
vegf
pathway
vegfa
block
angiogenesi
hsv
infect
cocktail
three
sirna
administ
either
subconjunctiv
inject
ag
tail
vein
iv
inject
ag
complex
rpp
polym
see
use
antivegf
cocktail
method
treatment
significantli
improv
clinic
angiogen
score
rel
control
sirna
subconjunctiv
administr
reduc
vegf
mrna
infect
cornea
approxim
sixfold
system
administr
achiev
approxim
twofold
reduct
use
fourfold
higher
dose
sirna
antisens
oligonucleotid
long
histori
success
use
neurosci
research
although
charg
nucleic
acid
readili
cross
bloodbrain
barrier
oligonucleotid
directli
inject
cn
compar
plasma
mani
tissu
cn
rel
bnucleasepoorq
environ
antisens
oligonucleotid
minim
modif
employ
good
result
therefor
surpris
direct
inject
unmodifi
sirna
cn
met
success
dorn
colleagu
report
use
minim
modifi
sirna
administ
use
implant
intrathec
pump
rat
cn
modul
chronic
neuropath
pain
rna
duplex
modifi
residu
moemodifi
phosphorothio
linkag
compris
overhang
strand
target
painrel
cationchannel
sirna
administ
continu
infus
dose
agday
mgkg
day
dorsal
root
ganglia
reduct
mrna
protein
rat
exhibit
attenu
pain
respons
sever
model
neuropath
pain
includ
tactil
allodynia
agonistinduc
mechan
hyperalgesia
thakker
colleagu
report
knockdown
two
target
mous
brain
use
direct
cn
administr
moemodifi
sirna
alzet
osmot
minipump
deliv
agday
sirna
mgkg
dorsal
third
ventricl
first
seri
studi
antiegfp
sirna
infus
egfpexpress
mice
follow
week
infus
effect
egfp
fluoresc
rang
suppress
locu
coeruleu
spinal
trigemin
nucleu
suppress
dentat
gyru
hippocampu
sirna
target
dopamin
transport
dat
gene
also
infus
found
reduc
dat
mrna
level
produc
tempor
hyperlocomotor
respons
similar
seen
use
smallmolecul
antagonist
dat
infus
sirna
target
serotonin
transport
sert
reduc
sert
mrna
level
produc
antidepressantlik
respons
similar
observ
administr
citalopram
smallmolecul
serotoninreuptak
inhibitor
use
cation
lipid
deliveri
agent
may
enabl
lower
dose
sirna
use
kind
studi
safe
use
cn
luo
colleagu
deliv
unmodifi
control
sirna
sirna
specif
delta
opioid
receptor
dor
via
implant
intrathec
cathet
lumbar
spine
rat
dose
rang
agday
given
al
solut
cation
lipid
ifect
low
dose
agkg
fluoresc
signal
readili
visual
spinal
cord
dorsal
root
ganglia
use
dyelabel
sirna
cation
lipid
unassist
infus
dor
protein
level
markedli
reduc
examin
immunohistochemistri
h
last
dose
sirna
antidortr
anim
mismatch
controltr
anim
level
relat
mu
opioid
receptor
unchang
demonstr
specif
function
treatment
antidor
sirna
specif
block
antinocicept
effect
dor
agonist
although
eight
group
publish
data
show
success
use
sirna
cn
studi
two
group
report
neg
result
use
sirna
valid
vitro
number
group
report
success
use
direct
inject
adjac
tumor
mass
use
nake
andor
complex
sirna
aharinejad
colleagu
report
direct
inject
unmodifi
sirna
subcutan
mass
human
mammari
tumor
cell
line
nude
mice
inject
start
tumor
establish
begin
day
implant
dose
ag
everi
day
week
two
differ
sirna
specif
murin
colonystimul
factor
csf
receptor
cfm
protooncogen
employ
signal
recruit
macrophag
infiltr
tumor
sever
macrophagederiv
factor
believ
facilit
metastasi
tumor
growth
matrix
metalloproteas
vegf
sirna
test
vitro
activ
sequenc
employ
subsequ
vivo
experi
mrna
level
reduc
tumor
tissu
consist
origin
hypothesi
metalloproteas
level
vegf
level
also
reduc
tumor
treatment
tumor
growth
reduc
leng
mixon
use
cation
peptid
facilit
deliveri
unmodifi
sirna
direct
inject
human
breast
cancer
implant
nude
mice
sirna
employ
specif
member
raf
kinas
famili
involv
rasmek
signal
seri
structur
differ
histidinelysin
peptid
synthes
compar
dotap
liposom
abil
deliv
sirna
mice
inject
contain
ag
peptid
complex
ag
sirna
administ
everi
day
two
three
dose
h
sirna
complex
effect
reduc
tumor
size
rel
treatment
control
sirnapeptid
superior
liposom
prepar
atelocollagen
also
use
assist
direct
intratumor
inject
takei
colleagu
describ
inject
unmodifi
antivegf
sirna
al
solut
atelocollagen
pb
establish
human
prostat
cancer
cell
implant
nude
mice
doserespons
curv
perform
use
concentr
sirna
ag
inject
done
everi
day
tumor
respons
assess
day
treatment
antivegf
sirna
reduc
tumor
volum
dosedepend
fashion
use
highest
dose
tumor
smaller
control
sirnatr
mice
reduct
vegf
protein
observ
day
tumor
treat
antivegf
sirna
properti
atelocollagen
deliveri
agent
also
describ
tumor
inject
fluoresc
dyelabel
sirna
atelocollagen
significantli
label
cell
also
bbrighterq
tumor
inject
nake
sirna
intact
plabel
sirna
could
detect
tumor
day
inject
atelocollagen
wherea
nake
sirna
mostli
undetect
day
postinject
nucleic
acid
absorb
epitheli
mucos
surfac
maeda
colleagu
describ
use
deliveri
rout
administ
unmodifi
sirna
murin
deaf
model
system
gene
gap
junction
protein
encod
transmembran
protein
involv
potassium
recycl
auditori
signal
allel
variant
gene
implic
sever
form
hereditari
deaf
dominantneg
mutant
gene
fuse
egfp
use
creat
model
human
deaf
mice
sirna
deliv
cochlea
mice
mixtur
dotapcholesterol
liposom
geneshuttl
use
ag
sirna
al
soak
piec
gel
foam
surgic
place
round
window
membran
administr
sirna
reduc
express
mrna
without
affect
level
normal
murin
revers
auditori
impair
caus
express
mutant
human
gene
mous
cochlea
pallis
colleagu
use
unmodifi
sirna
cation
lipid
carrier
bmicrobicideq
appli
intravagin
block
infect
mice
mice
vagin
infect
pfu
ld
dose
given
control
sirna
h
hq
time
point
hq
time
point
duplex
target
sever
viral
gene
compar
one
target
viral
potent
suppress
viru
product
vitro
sirna
administ
intravagin
describ
dose
nmol
ag
volum
complex
oligofectamin
mice
receiv
sirna
surviv
day
mice
receiv
control
sirna
surviv
mice
receiv
sirna
target
differ
viral
gene
surviv
importantli
evid
activ
innat
immun
system
detect
follow
sirna
treatment
absenc
viral
infect
ifnh
mrna
level
test
qrtpcr
thu
two
independ
sirna
show
similar
biolog
effect
evid
immun
stimul
antivir
effect
could
attribut
directli
rnaimedi
suppress
deliveri
sirna
liposom
cation
lipid
bpaintq
might
similarli
use
epitheli
surfac
oral
rectal
mucosa
antisens
oligonucleotid
administ
inhal
treat
asthma
pulmonari
diseas
similarli
sever
group
deliv
sirna
intranas
intratrach
infus
mice
massaro
colleagu
describ
intranas
administr
sirna
smallmolecul
compound
mice
infasurf
replac
pulmonari
surfact
commonli
use
treat
neonat
sever
respiratori
distress
syndrom
unmodifi
sirna
target
gapdh
administ
intranas
lightli
anesthet
mice
dose
ag
volum
h
postinfus
gapdh
protein
level
reduc
lung
heart
kidney
liver
brain
day
gapdh
suppress
control
level
lung
tissu
show
limit
effect
number
group
explor
use
sirna
treat
respiratori
virus
use
direct
pulmonari
deliveri
mammal
tompkin
colleagu
use
unmodifi
sirna
specif
viral
np
pa
protein
protect
mice
lethal
infect
influenza
viru
sirna
pb
administ
iv
hd
tail
vein
inject
h
prior
infect
singl
dose
ag
mgkg
influenza
viru
coadminist
sirna
complex
cation
lipid
oligofectamin
direct
intranas
infus
mice
dose
nmol
ag
mgkg
viral
titer
lung
tissu
reduc
much
use
antiinfluenza
sirna
compar
control
sirna
surviv
significantli
improv
especi
mice
receiv
combin
antinp
antipa
sirna
bitko
colleagu
describ
use
unmodifi
sirna
treat
pulmonari
infect
respiratori
syncyti
viru
rsv
parainfluenza
viru
mice
target
viral
p
gene
virus
sirna
pb
administ
either
nake
complex
cation
lipid
transittko
direct
intranas
infus
mice
dose
ag
nostril
ag
total
dose
mgkg
treatment
nake
sirna
effect
cation
lipid
mice
receiv
antivir
sirna
show
decreas
lung
patholog
overal
distress
compar
mice
receiv
control
sirna
although
greatest
improv
seen
treatment
start
time
infect
benefit
seen
sirna
treatment
given
even
day
postinfect
sever
acut
respiratori
syndrom
coronaviru
scv
subject
intens
investig
recent
year
develop
kind
therapeut
method
treat
viru
support
care
high
prioriti
li
colleagu
describ
use
unmodifi
sirna
deliv
intranas
rhesu
macaqu
macaca
mulatta
deliveri
sirna
target
report
construct
first
test
use
infasurf
via
intranas
deliveri
mice
carrier
gave
superior
result
therefor
employ
primat
studi
mixtur
two
sirna
specif
spike
proteincod
region
administ
h
prior
infect
singl
dose
time
infect
day
postinfect
h
postinfect
day
postinfect
dose
mg
ml
total
cumul
dose
mg
sirna
mgkg
sever
symptom
improv
treatment
group
anim
test
day
postinfect
presenc
scv
rna
use
qrtpcr
assay
oropharyng
swab
sampl
control
anim
posit
scv
viral
rna
antiscv
sirnatr
anim
detect
viral
rna
electropor
use
tool
transfect
sirna
vitro
cell
line
refractori
cation
lipidmedi
transfect
interestingli
also
employ
assist
sirna
deliveri
vivo
golzio
colleagu
describ
electroporationassist
deliveri
egfp
express
plasmid
without
unmodifi
antiegfp
sirna
follow
direct
inject
mous
muscl
pb
egfp
fluoresc
specif
reduc
antiegfp
control
sirna
target
endogen
target
describ
schiffel
colleagu
use
electropor
assist
deliveri
unmodifi
sirna
target
tnfa
mice
collageninduc
arthriti
inject
egfp
express
plasmid
knee
joint
mice
show
local
express
egfp
electropor
employ
coadministr
inject
electropor
ag
luciferas
express
plasmid
ag
either
antiegfp
control
antiluc
sirna
show
suppress
luciferas
activ
antiluc
sirna
use
collageninduc
arthriti
induc
inject
mice
type
ii
collagen
inflamm
trigger
ip
inject
lp
day
second
dose
collagen
antitnfa
sirna
treatment
initi
day
lp
treatment
dose
ag
direct
inject
electropor
knee
joint
administ
weekli
three
dose
anim
treat
antitnfa
sirna
show
mark
improv
inflamm
reduc
arthriti
score
rel
control
anim
similarli
inou
colleagu
use
electropor
assist
deliveri
unmodifi
sirna
target
tnfa
rat
collageninduc
arthriti
case
nmol
ag
antitnfa
sirna
control
sirna
inject
knee
joint
rat
cation
lipid
siport
amin
follow
electropor
tnfa
mrna
level
reduc
synovi
tissu
inflamm
markedli
reduc
assess
paw
swell
histolog
examin
antitnfatr
anim
rel
control
addit
chemic
electr
method
promot
deliveri
sirna
vivo
discuss
kim
colleagu
describ
mechan
method
use
gold
nanoparticl
gene
gun
context
improv
immun
respons
mice
dna
vaccin
infect
human
papillomaviru
type
associ
develop
cervic
carcinoma
attempt
immun
mice
use
dna
vaccin
plasmid
express
gene
result
incomplet
respons
partial
due
transient
natur
antigen
present
resid
antigenpres
cell
apc
author
test
coadministr
plasmid
sirna
target
proapoptot
gene
bax
bak
would
prolong
surviv
apc
improv
vaccin
nucleic
acid
coat
onto
gold
microcarri
deliv
subderm
use
helio
gene
gun
dose
ag
plasmid
coadminist
ag
unmodifi
antibak
antibax
sirna
vaccin
deliv
bak
bax
sirna
increas
number
antigenspecif
ifng
cell
precursor
mice
receiv
combin
vaccin
bax
bak
sirna
show
mark
reduct
tumor
burden
inject
cell
express
antigen
compar
mice
receiv
vaccin
control
sirna
kinoshita
hynynen
describ
use
microbubbl
focus
ultrasound
sonopor
deliv
sirna
cell
vitro
tsunoda
colleagu
use
sonopor
deliv
egfp
express
plasmid
without
unmodifi
antiegfp
sirna
cardiac
tissu
mice
egfp
express
plasmid
inject
left
ventricl
anesthet
mice
ag
al
pb
al
microbubbl
transthorac
ultrasound
stimul
appli
egfp
fluoresc
detect
cardiac
ventricular
wall
coronari
arteri
coinject
ag
antiegfp
sirna
suppress
egfp
fluoresc
pharmaceut
biotechnolog
compani
declar
interest
activ
drug
develop
program
alreadi
way
rnaibas
therapeut
number
compani
drug
develop
program
outlin
tabl
addit
mani
larg
pharmaceut
compani
tradit
associ
smallmolecul
drug
develop
also
activ
intern
collabor
rnairel
drug
develop
project
sirna
therapeut
report
interim
result
phase
studi
american
societi
gene
therapi
confer
june
chemic
modifi
sirna
drug
target
treat
agerel
macular
degener
amd
studi
involv
administr
singl
escal
dose
drug
direct
intravitr
inject
dose
ag
administ
signific
toxic
observ
brief
observ
period
visual
acuiti
stabil
even
improv
dosedepend
manner
preclin
studi
mous
model
system
also
report
john
hopkin
univers
acuiti
pharmaceut
report
result
phase
clinic
trial
sirna
drug
target
vegf
drug
treat
amd
octob
meet
american
academi
ophthalmolog
fifteen
patient
administ
five
escal
dose
level
mg
per
eye
direct
intravitr
inject
advers
effect
relat
actual
sirna
drug
report
howev
expect
side
effect
subconjunctiv
hemorrhag
etc
observ
normal
rout
drug
administr
system
deliveri
detect
patient
current
enrol
phase
ii
clinic
trial
alnylam
pharmaceut
drug
develop
program
ongo
multipl
indic
specif
partner
novarti
merck
medtron
certain
project
advanc
drug
pipelin
target
rsv
ind
file
novemb
fda
lead
compound
treatment
pandem
influenza
next
develop
pipelin
alnylam
plan
file
ind
field
later
mani
compani
report
preclin
data
valid
sirna
drug
develop
project
vivo
mammalian
model
system
nastech
pharmaceut
work
mayo
clinic
present
data
use
antitnfa
sirna
deliv
use
peptid
carrier
system
treat
rheumatoid
arthriti
novemb
american
colleg
rheumatolog
meet
alnylam
pharmaceut
publish
preclin
work
relat
treatment
hypercholesterolemia
use
antiapob
sirna
sirna
therapeut
publish
preclin
work
relat
treatment
hepat
b
infect
protiva
biotherapeut
provid
snalp
deliveri
system
calando
pharmaceut
publish
result
collabor
studi
relat
sirna
treatment
ewe
sarcoma
children
hospit
lo
angel
galenea
describ
use
sirna
treat
influenza
mice
work
done
mit
intradigm
publish
number
collabor
studi
done
relat
sirna
treatment
cancer
arthriti
ocular
diseas
viral
diseas
abbott
describ
use
sirna
mous
cancer
model
system
novarti
report
use
sirna
cn
studi
transgenex
nanobiotech
chitosan
deliveri
system
employ
report
use
ddrnai
treat
rsv
univers
south
florida
neopharm
publish
use
liposom
deliv
sirna
two
mous
cancer
model
system
one
georgetown
univers
medic
center
miru
publish
use
hydrodynam
deliveri
system
mice
larger
mammal
univers
wisconsin
madison
wi
usa
consid
rel
youth
rnai
field
remark
number
vivo
studi
alreadi
publish
relat
preclin
develop
sirna
drug
use
sirna
method
valid
target
smallmolecul
drug
develop
project
rna
interfer
proven
extrem
potent
versatil
tool
specif
reduc
express
target
gene
use
technolog
rapidli
move
vitro
cell
cultur
studi
vivo
administr
mammal
address
question
basic
biolog
drug
develop
program
rnaibas
drug
alreadi
clinic
trial
hope
sirna
therapeut
receiv
fda
approv
distant
futur
understand
basic
biochemistri
biolog
rnai
advanc
becom
clear
extra
control
employ
use
sirna
vivo
avoid
risk
misinterpret
result
due
unintend
stimul
innat
immun
system
offtarget
effect
publish
studi
actual
measur
cytokin
level
simpli
employ
bcontrolq
sirna
ensur
immun
stimul
unintend
event
occur
given
sequencespecif
natur
innat
immun
respons
confid
kind
control
may
misplac
even
modifi
sirna
lower
incid
immun
stimul
employ
measur
serum
ifna
tnfa
possibl
level
h
posttreat
consid
especi
system
administr
method
employ
local
administr
employ
assay
includ
extract
prepar
inject
site
organ
well
serum
offtarget
effect
difficult
identifi
also
sequenc
specif
microarray
use
assess
extent
ote
gene
express
level
genomewid
scale
studi
done
cell
cultur
howev
kind
experi
report
yet
vivo
kind
data
might
difficult
interpret
one
approach
control
ote
would
requir
use
two
differ
sirna
target
expect
result
suppress
target
gene
produc
biolog
respons
phenotyp
vivo
studi
report
date
confirm
result
use
two
independ
sirna
sequenc
studi
discuss
perform
kind
doserespons
optim
sirna
reagent
vivo
instead
simpli
report
result
use
singl
dose
regimen
even
though
studi
expens
perform
mammal
import
character
system
fulli
kind
inform
may
uncov
dosedepend
side
effect
actual
oterel
event
probabl
show
variat
individu
especi
outbr
popul
make
control
even
import
includ
set
although
lab
report
success
use
vivo
administr
nake
sirna
greater
number
investig
report
use
kind
deliveri
system
improv
result
rout
administr
choic
deliveri
tool
use
crucial
success
hydrodynam
deliveri
vivo
studi
publish
use
singl
method
accumul
amount
inform
need
assess
function
perform
adequ
differ
target
gene
differ
target
tissu
permit
gener
endors
method
although
sever
approach
seem
quit
promis
unfortun
mani
advanc
deliveri
system
employ
studi
discuss
avail
research
widespread
adopt
rnai
use
synthet
sirna
vivo
research
tool
acceler
effect
mammalian
deliveri
tool
becom
commerci
avail
target
tissu
system
studi
permit
use
local
deliveri
approach
method
may
easier
perform
use
boff
shelfq
tool
offer
greater
assur
success
system
iv
administr
